The Top 5 Biosimilars Articles for the Week of May 6

May 10, 2019

The Center for Biosimilars® recaps the top news for the week of May 6, 2019.

Transcript:

Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of May 6.

Number 5: Last week, Coherus BioSciences announced that it has reached a settlement with Amgen over a trade secret case. Separately, Amgen filed a new complaint against Samsung Bioepis.

Number 4: The pan-Canadian Pharmaceutical Alliance and Cancer Care Ontario have partnered to create a new biosimilars initiative.

Number 3: Now that its comment period has closed, the FDA has heard from a variety of stakeholders who asked the agency to reconsider its guidance on biosimilar naming.

Number 2: A new review of the available literature on switching sought to address provider concerns about biosimilars.

Number 1: The idea of giving the Federal Trade Commission more authority to cut through patent thickets blocking biosimilar competition was raised during a hearing of the Senate Judiciary Committee.

Finally, last week, our e-newsletter asked whether you agree with a recent proposal that suggests regulating biologics’ prices rather than continuing to develop the US biosimilars market.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Content:

News | Business | Policy | Regulatory

x